Training and Events
Designing Phase I Dose Escalation Studies
Dr Thomas Jaki
04/06/2018 - 05/06/2018
Department of Mathematics and Statistics
View in Google Maps (LA1 4YF)
Angela Mercer, Tel: 01524 593064, email@example.com
The importance of exploratory clinical research prior to the launch of a large-scale definitive phase III clinical trial is becoming increasingly recognised, both in the pharmaceutical industry and in public sector medical research. Dose-escalation studies are first-in-human studies intending to determine a safe dose or range of doses which can be taken forward for further development. Advances in the identification of medical biomarkers of therapeutic effect and in statistical techniques based on adaptive designs and Bayesian inference now allow such studies to be designed efficiently, to take account of information from a variety of sources and to combine objectives such as establishing safety and seeking evidence of a potential benefit.
This course presents state of the art methodology for dose-escalation studies. The course will be delivered through a mixture of lectures, practical sessions and discussion sessions.
Intermediate (some prior knowledge)
External from industry/commerce £540; External from academic institution/public sector/charity staff £460; External postgraduate student £300
Website and registration
Quantitative Data Handling and Data Analysis
Related publications and presentations